Table 3 Results of subgroup analysis of included trials in meta-analysis
From: Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis
Groups | n | Allopurinol | n | The model group | ||||
|---|---|---|---|---|---|---|---|---|
WMD (95%CI) | P-value | I2 | WMD (95%CI) | P-value | I2 | |||
Material | ||||||||
 Metal | 3 | 0.382(-0.358, 1.121) | 0.312 | 0.00% | 3 | -7.414(-8.563, -6.264) | 0.000 | 0.00% |
 Non-metal | 6 | -0.257(-0.489, -0.024) | 0.030 | 52.90% | 8 | -4.336(-4.886, -3.785) | 0.000 | 93.30% |
Animal species | ||||||||
 BALB/c | 6 | -0.330(-0.580, -0.081) | 0.010 | 39.50% | 6 | -7.771(-8.545, -6.997) | 0.000 | 0.00% |
 SD | 3 | 0.293(-0.191, 0.776) | 0.236 | 0.00% | 5 | -2.906(-3.553, -2.258) | 0.000 | 88.90% |
Dosage | ||||||||
 H | 3 | -0.265(-0.655, 0.126) | 0.185 | 59.00% | 4 | -4.486(-5.269, -3.703) | 0.001 | 94.60% |
 M | 3 | 0.130(-0.297, 0.557) | 0.550 | 0.00% | 4 | -4.314(-5.109, -3.519) | 0.001 | 93.80% |
 L | 3 | -0.366(-0.713, -0.019) | 0.039 | 58.50% | 3 | -6.850(-7.939, -5.761) | 0.000 | 69.70% |
Quantity | ||||||||
 6 | 6 | -0.330(-0.580, -0.081) | 0.010 | 39.50% | 8 | -4.876(-5.460, -4.291) | 0.000 | 94.50% |
 8 | 3 | 0.293(-0.191, 0.776) | 0.236 | 0.00% | 3 | -4.998(-5.939, -4.057) | 0.000 | 0.00% |
Gender | ||||||||
 F; M | 6 | -0.330(-0.580, -0.081) | 0.010 | 39.50% | 6 | -7.771(-8.545, -6.997) | 0.000 | 0.00% |
 M | 3 | 0.293(-0.191, 0.776) | 0.236 | 0.00% | 5 | -2.906(-3.553, -2.258) | 0.000 | 88.90% |